Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,502 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03783442 | A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma | completed | Phase 3 | 649 | BeiGeneINDUSTRY | 16 | Jul 29, 2025 | clinicaltrials |
| NCT02975934 | A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency(TRITON3) | completed | Phase 3 | 405 | pharmaand GmbHINDUSTRY | 12 |
| Jul 25, 2025 |
| clinicaltrials |
| NCT05458856 | Effects of Triptorelin When Given Every 6-months Under the Skin to Adult Males With Cancer in the Prostate(TriptoSwitch) | completed | Phase 3 | 147 | IpsenINDUSTRY | 7 | Jul 25, 2025 | clinicaltrials |
| NCT04026412 | A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery(CheckMate73L) | completed | Phase 3 | 925 | Bristol-Myers SquibbINDUSTRY | 27 | Jul 24, 2025 | clinicaltrials |
| NCT03112174 | Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)(SYMPATICO) | completed | Phase 3 | 366 | Pharmacyclics LLC.INDUSTRY | 17 | Jul 22, 2025 | clinicaltrials |
| NCT04832607 | Multivirus-specific T-cell Transfer Post SCT vs AdV, CMV and EBV Infections(TRACE) | recruiting | Phase 3 | 149 | Tobias FeuchtingerOTHER | 6 | Jul 18, 2025 | clinicaltrials |
| NCT04915755 | Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease(ZEST) | active not recruiting | Phase 3 | 40 | GlaxoSmithKlineINDUSTRY | 27 | Jul 16, 2025 | clinicaltrials |
| NCT02451943 | A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma(ANNOUNCE) | completed | Phase 3 | 509 | Eli Lilly and CompanyINDUSTRY | 25 | Jul 15, 2025 | clinicaltrials |
| NCT04752332 | A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer(eMonarcHER) | terminated | Phase 3 | 111 | Eli Lilly and CompanyINDUSTRY | 20 | Jul 15, 2025 | clinicaltrials |
| NCT03725059 | Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756) | active not recruiting | Phase 3 | 1,240 | Merck Sharp & Dohme LLCINDUSTRY | 24 | Jul 11, 2025 | clinicaltrials |
| NCT02885753 | Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver(OSCAR) | recruiting | Phase 3 | 348 | Federation Francophone de Cancerologie DigestiveOTHER | 2 | Jul 9, 2025 | clinicaltrials |
| NCT01757535 | Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia (AML) in Complete Remission(QUAZAR AML-001) | completed | Phase 3 | 472 | CelgeneINDUSTRY | 23 | Jul 8, 2025 | clinicaltrials |
| NCT01776840 | A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma | completed | Phase 3 | 523 | Janssen Research & Development, LLCINDUSTRY | 28 | Jul 8, 2025 | clinicaltrials |
| NCT03345095 | A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma(MIRAGE) | completed | Phase 3 | 749 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 12 | Jul 1, 2025 | clinicaltrials |
| NCT05692999 | Maintenance Pembrolizumab at Usual or Low doSE in Non-squamous Lung Cancer: a Non-inferiority Study(Pulse) | recruiting | Phase 3 | 1,166 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 3 | Jun 25, 2025 | clinicaltrials |
| NCT03045406 | Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer(CARAVAGGIO) | completed | Phase 3 | 1,170 | Fadoi Foundation, ItalyOTHER | 11 | Jun 24, 2025 | clinicaltrials |
| NCT03522246 | A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy(ATHENA) | active not recruiting | Phase 3 | 1,097 | pharmaand GmbHINDUSTRY | 24 | Jun 24, 2025 | clinicaltrials |
| NCT00981058 | First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin(SQUIRE) | completed | Phase 3 | 1,093 | Eli Lilly and CompanyINDUSTRY | 26 | Jun 18, 2025 | clinicaltrials |
| NCT02667587 | An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)(CheckMate548) | completed | Phase 3 | 716 | Bristol-Myers SquibbINDUSTRY | 19 | Jun 18, 2025 | clinicaltrials |
| NCT04100018 | A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer(CheckMate 7DX) | completed | Phase 3 | 1,030 | Bristol-Myers SquibbINDUSTRY | 28 | Jun 12, 2025 | clinicaltrials |
| NCT03800134 | A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer(AEGEAN) | active not recruiting | Phase 3 | 825 | AstraZenecaINDUSTRY | 28 | Jun 11, 2025 | clinicaltrials |
| NCT03072238 | Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer(IPATential150) | completed | Phase 3 | 1,101 | Hoffmann-La RocheINDUSTRY | 26 | Jun 6, 2025 | clinicaltrials |
| NCT01974440 | A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma(SELENE) | completed | Phase 3 | 403 | Janssen Research & Development, LLCINDUSTRY | 19 | May 25, 2025 | clinicaltrials |
| NCT01844505 | Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067) | completed | Phase 3 | 945 | Bristol-Myers SquibbINDUSTRY | 22 | May 21, 2025 | clinicaltrials |
| NCT02577406 | An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation(IDHENTIFY) | completed | Phase 3 | 319 | CelgeneINDUSTRY | 18 | May 18, 2025 | clinicaltrials |
| NCT02467582 | Adjuvant Aspirin Treatment for Colon Cancer Patients | terminated | Phase 3 | 1,040 | Swiss Cancer InstituteOTHER | 4 | May 16, 2025 | clinicaltrials |
| NCT04427072 | Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation(GeoMETry-III) | terminated | Phase 3 | 22 | Novartis PharmaceuticalsINDUSTRY | 18 | May 16, 2025 | clinicaltrials |
| NCT02807181 | SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma(SIRCCA) | terminated | Phase 2 / Phase 3 | 89 | Sirtex MedicalINDUSTRY | 8 | May 9, 2025 | clinicaltrials |
| NCT03158688 | Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.(CANDOR) | completed | Phase 3 | 466 | AmgenINDUSTRY | 19 | May 9, 2025 | clinicaltrials |
| NCT02076009 | A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma | completed | Phase 3 | 569 | Janssen Research & Development, LLCINDUSTRY | 18 | May 1, 2025 | clinicaltrials |
| NCT02388906 | Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma(CheckMate 238) | completed | Phase 3 | 906 | Bristol-Myers SquibbINDUSTRY | 25 | Apr 24, 2025 | clinicaltrials |
| NCT02541383 | A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma(Cassiopeia) | completed | Phase 3 | 1,085 | Intergroupe Francophone du MyelomeNETWORK | 3 | Apr 13, 2025 | clinicaltrials |
| NCT03903835 | ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer(ProBio) | recruiting | Phase 3 | 750 | Karolinska InstitutetOTHER | 4 | Apr 9, 2025 | clinicaltrials |
| NCT02288247 | A Study to Assess the Benefit of Treatment Beyond Progression With Enzalutamide in Men Who Are Starting Treatment With Docetaxel After Worsening of Their Prostate Cancer When Taking Enzalutamide Alone(PRESIDE) | completed | Phase 3 | 688 | Astellas Pharma Europe Ltd.INDUSTRY | 16 | Apr 8, 2025 | clinicaltrials |
| NCT03257267 | Study of Cemiplimab in Adults With Cervical Cancer | completed | Phase 3 | 608 | Regeneron PharmaceuticalsINDUSTRY | 14 | Apr 8, 2025 | clinicaltrials |
| NCT03631706 | M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC) | completed | Phase 3 | 304 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 18 | Apr 8, 2025 | clinicaltrials |
| NCT03353831 | Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer | completed | Phase 3 | 574 | AGO Research GmbHINDUSTRY | 12 | Apr 6, 2025 | clinicaltrials |
| NCT02017717 | A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients(CheckMate 143) | completed | Phase 3 | 529 | Bristol-Myers SquibbINDUSTRY | 12 | Apr 4, 2025 | clinicaltrials |
| NCT04322539 | A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer(FRESCO-2) | completed | Phase 3 | 691 | Hutchison Medipharma LimitedINDUSTRY | 14 | Apr 4, 2025 | clinicaltrials |
| NCT05079230 | Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia(ENHANCE-3) | terminated | Phase 3 | 378 | Gilead SciencesINDUSTRY | 20 | Apr 4, 2025 | clinicaltrials |
| NCT03635983 | A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma | completed | Phase 3 | 783 | Bristol-Myers SquibbINDUSTRY | 27 | Apr 1, 2025 | clinicaltrials |
| NCT03734016 | A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia(ALPINE) | completed | Phase 3 | 652 | BeiGeneINDUSTRY | 15 | Mar 30, 2025 | clinicaltrials |
| NCT04199689 | Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049) | active not recruiting | Phase 3 | 6,033 | Merck Sharp & Dohme LLCINDUSTRY | 16 | Mar 25, 2025 | clinicaltrials |
| NCT02641639 | FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer | terminated | Phase 2 / Phase 3 | 70 | Mateon TherapeuticsINDUSTRY | 3 | Mar 24, 2025 | clinicaltrials |
| NCT00490139 | ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D(ALTTO) | completed | Phase 3 | 8,381 | Novartis PharmaceuticalsINDUSTRY | 44 | Mar 21, 2025 | clinicaltrials |
| NCT00667251 | Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer | completed | Phase 3 | 652 | Novartis PharmaceuticalsINDUSTRY | 21 | Mar 21, 2025 | clinicaltrials |
| NCT02492711 | Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer(SOPHIA) | completed | Phase 3 | 624 | MacroGenicsINDUSTRY | 18 | Mar 17, 2025 | clinicaltrials |
| NCT01160211 | A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer | completed | Phase 3 | 369 | Novartis PharmaceuticalsINDUSTRY | 29 | Mar 7, 2025 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials